Let's cut through the noise. Everyone's looking for the next hot stock, but chasing trends is a recipe for anxiety and poor returns. Based on two decades of navigating bull and bear markets, I've found that the best approach is often the simplest: identify great businesses at reasonable prices and hold them. It's not sexy, but it works. So, if you're asking "What are the top three stocks to buy right now?" my answer focuses on foundational strength, not fleeting momentum. Here are my current top picks, complete with the specific rationale and price levels I'm watching.

What You'll Find in This Guide

Pick #1: Microsoft Corporation (MSFT)

This isn't a surprise pick, and that's precisely the point. Microsoft is the definition of a fortress business. I've held shares through various cycles, and what keeps me invested is the sheer breadth and durability of its cash flows. It's not just Windows anymore; it's the plumbing of the modern digital economy.

Why Microsoft Makes the List

The Azure Engine: While Amazon's AWS gets more buzz for pioneering cloud, Azure's growth, especially within large enterprises and governments, is relentless. In my conversations with IT managers, the seamless integration with the existing Microsoft ecosystem (Office, Windows Server, Active Directory) is a recurring, unbeatable advantage. It creates a sticky, high-switching-cost environment.

Productivity Suite Dominance: Teams, Office 365, LinkedIn. These aren't just products; they're daily habits for hundreds of millions. The revenue is recurring and predictable. Even in a downturn, businesses cut travel before they cancel their Office licenses.

AI Integration Lead: Unlike many companies just starting to talk about AI, Microsoft has already productized it at scale with Copilot across its suite. They're monetizing AI today, not in some distant future.

The Risk Everyone Underestimates

Regulatory scrutiny. Microsoft is now so large and embedded in critical infrastructure that it's a permanent fixture in the sights of regulators globally. A major antitrust action, while unlikely to break up the company, could cap its growth ambitions or lead to costly settlements. It's a headwind you must accept when investing in a giant.

My Actionable Take

I'm not chasing MSFT when it's hitting all-time highs. Patience is key. I'm looking for entry points below $400 per share, which often comes during broader market pullbacks or sector rotations out of tech. It's a core holding, so you scale in. Don't try to buy it all at once.

Pick #2: Berkshire Hathaway Inc. (BRK.B)

Think of this as buying a diversified, actively managed ETF run by the most seasoned capital allocators in history (Warren Buffett and Charlie Munger's legacy team). For investors who don't have the time or skill to analyze individual businesses, BRK.B is a cheat code. I own the B shares for their liquidity and accessibility.

Here’s a snapshot of what you're really buying—a slice of these wholly-owned businesses and massive stock holdings:

Business Segment Key Examples Why It Matters
Insurance "Float" Engine GEICO, Berkshire Hathaway Reinsurance Provides a massive, low-cost pool of capital (premiums collected before claims are paid) to invest. This is Berkshire's secret weapon.
Diverse Operating Businesses BNSF Railway, Berkshire Hathaway Energy, See's Candies, Duracell Steady, cash-generating businesses with strong competitive moats. They perform well in various economic conditions.
Public Equity Portfolio Apple, Bank of America, American Express, Coca-Cola A concentrated bet on high-quality companies, largely assembled by Buffett himself. You get this portfolio by proxy.

The Hidden Advantage Most Miss

It's a capital compounder, not a growth stock. Berkshire rarely pays a dividend and doesn't buy back stock aggressively unless it's deeply undervalued. Instead, it relentlessly reinvests all that cash flow into buying more businesses and stocks. You're betting on the compounding skill of its management, which has a track record spanning decades.

Personal Note: During volatile markets, I've found my Berkshire holdings provide immense psychological comfort. The portfolio is built for storms—full of essential services (railroads, utilities) and brands people don't stop using. It lets me sleep well.

My Actionable Take

There's rarely a "bad" time to buy BRK.B for the long term, but better times exist. I watch for periods when it's trading near or below its book value per share—a metric Buffett himself has highlighted. You can find this data in their quarterly reports. When the market is panicking about something short-term (like an insurance catastrophe quarter), that's often when I add a few more shares.

Pick #3: AbbVie Inc. (ABBV)

This pick addresses a major investor pain point: fear of the "patent cliff." AbbVie's blockbuster drug Humira, once the world's top-selling pharmaceutical, has faced generic competition. The stock got hammered for years in anticipation. But here's the non-consensus view I held through that period: management saw it coming a mile away and has been preparing brilliantly.

The story here is a successful transition. Sales from Humira are declining, but two newer immunology drugs, Skyrizi and Rinvoq, are growing explosively and are on track to more than fill the gap. I've followed the clinical trial data and prescription trends, and the uptake by dermatologists and rheumatologists is real.

The Bull Case for AbbVie

Pipeline Execution: They didn't just replace Humira; they created arguably superior drugs with more convenient dosing. This execution risk was the biggest hurdle, and they've cleared it.

Diversified Growth: Beyond immunology, their neuroscience portfolio (Vraylar) and aesthetics business (Botox, Juvederm) are major cash cows with durable demand.

A Dividend Aristocrat on Sale: AbbVie has a stellar history of raising its dividend. The yield is often attractive (recently around 3.7%), and the stock price has been depressed due to the Humira overhang, creating a compelling total return opportunity.

The Real Risk Here

Pipeline stagnation. The pharmaceutical industry is a treadmill. You must constantly innovate. While Skyrizi and Rinvoq are hits, AbbVie needs the next wave of candidates in mid-to-late-stage trials to succeed. Any major clinical failure in their next-generation pipeline could reset growth expectations.

My Actionable Take

The time to buy was when everyone was terrified about the patent cliff. That fear has largely played out. Now, I'm looking for confirmation that the new drug growth is sustainable. I like ABBV below $160 as a starting point for a position. It's a play on management credibility and the steady, recurring nature of healthcare spending.

How to Approach Buying These Stocks

Throwing money at these names without a plan is a mistake. Here's the framework I use, honed from years of getting it wrong before getting it right.

1. Position Sizing: None of these should be your entire portfolio. I'd allocate no more than 5-7% of an equity portfolio to any single name, even one as robust as Microsoft. Start with a half-position (2.5-3.5%) and add on weakness.

2. Use Limit Orders, Not Market Orders: Never just click "buy." Decide your target entry price (like MSFT

3. Have a "Why" and a "When to Sell": My "why" for each is above. My "when to sell" is rarely based on price targets. It's based on a deterioration of the original thesis: e.g., Azure loses significant market share, Berkshire's post-Buffett capital allocation falters, AbbVie's pipeline dries up. If the core story is intact, I hold through volatility.

4. Reinvest Dividends: For ABBV and MSFT, set up dividend reinvestment (DRIP). Let compounding do its silent work in the background.

Common Questions Answered

Aren't these just boring, old companies? Shouldn't I be looking for high-growth stocks?
"Boring" companies that generate consistent, growing cash flows are what build wealth over time. High-growth stories are exciting but come with extreme volatility and high failure rates. For most investors, the primary goal isn't excitement; it's growing and preserving capital. These picks offer a balance of growth (Microsoft, AbbVie's new drugs) and stability (Berkshire's diverse empire), which is a more reliable path for a core portfolio.
How do I know if it's the right time to buy, or if I should wait for a crash?
You cannot time the market. The "right time" is when you have capital to invest and a long-term horizon. Trying to wait for a crash means you'll often be in cash while the market grinds higher. The strategy I outlined—using limit orders at specific price levels—is a disciplined way to buy on *your* terms during regular market dips without needing a catastrophic crash.
What's the biggest mistake you see beginners make when picking stocks like these?
They check the price daily. Once you've done your research and bought a company you believe in for the next 5-10 years, daily price movements are just noise. The constant checking leads to emotional decisions—selling in a panic or doubling down recklessly. Buy based on business fundamentals, set up alerts for earnings reports and major news, but otherwise, give your investments room to breathe. Quarterly review is more than enough.
Should I consider the overall market valuation before buying?
It's a background factor, not a primary driver. Yes, buying during periods of widespread market euphoria (like very high Shiller P/E ratios) can lead to lower future returns. But even in expensive markets, individual companies can be fairly valued or undervalued relative to their own prospects. Focus more on the valuation of the specific business you're buying versus its history and peers, rather than trying to call the top or bottom of the entire S&P 500.
How important are quarterly earnings reports for these stocks?
For Microsoft and AbbVie, very important for tracking the key metrics: Azure growth rate, Skyrizi/Rinvoq sales. For Berkshire, less so about quarterly profit (which is volatile due to investment gains/losses) and more about the growth in book value per share and the commentary from Buffett in the annual letter. Don't overreact to a single quarter's miss or beat. Look for trends over 4-8 quarters. Is the long-term thesis playing out as expected?

Investing isn't about finding a magic formula. It's about discipline, patience, and aligning your portfolio with businesses built to last. Microsoft, Berkshire Hathaway, and AbbVie represent three different paths to that goal: technological ubiquity, unparalleled capital allocation, and resilient healthcare innovation. Do your own research, tailor the sizing to your risk tolerance, and remember that time in the market is almost always more important than timing the market.